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Abdul Khalie Muhammad1, Brenda Kwambana-Adams1, Gemma L. Kay  2,5, 
Moumine Sanogo3, Bocar Baya3, Susan orsega6, Seydou Doumbia3, Souleymane Diallo3, 
Bouke c. de Jong4, Mark J. pallen  2,7 & Martin Antonio  1,2*
in recent years Bamako has been faced with an emerging threat from multidrug resistant tB (MDR-tB). 
Whole genome sequence analysis was performed on a subset of 76 isolates from a total of 208 
isolates recovered from tuberculosis patients in Bamako, Mali between 2006 and 2012. Among the 76 
patients, 61(80.3%) new cases and 15(19.7%) retreatment cases, 12 (16%) were infected by MDR-TB. 
The dominant lineage was the Euro-American lineage, Lineage 4. Within Lineage 4, the Cameroon 
genotype was the most prevalent genotype (n = 20, 26%), followed by the Ghana genotype (n = 16, 
21%). A sub-clade of the Cameroon genotype, which emerged ~22 years ago was likely to be involved 
in community transmission. A sub-clade of the Ghana genotype that arose approximately 30 years ago 
was an important cause of MDR-tB in Bamako. the Ghana genotype isolates appeared more likely to be 
MDR than other genotypes after controlling for treatment history. We identified a clade of four related 
Beijing isolates that included one MDR-TB isolate. It is a major concern to find the Cameroon and Ghana 
genotypes involved in community transmission and MDR-tB respectively. the presence of the Beijing 
genotype in Bamako remains worrying, given its high transmissibility and virulence.
Tuberculosis is caused by members of the Mycobacterium tuberculosis complex (MTBC). In humans, the main 
causes include Mycobacterium tuberculosis sensu stricto and Mycobacterium africanum1. M. tuberculosis and M. 
africanum form seven distinct phylogenetic lineages that are believed to have co-evolved with humans over mil-
lennia2–4. The East Asian, East-African-Indian and Euro-American lineages (Lineages 2,3 and 4 respectively) 
form the “modern” clade of tuberculosis5. The East Asian (including the Beijing genotype) and Euro-American 
lineages are the most widespread lineages globally and are probably more virulent than other lineages of the 
MTBC6. Recently a new lineage (lineage 7) has been discovered, which is predominantly restricted to Ethiopia in 
the horn of Africa7,8.
A unique feature of TB in West Africa is the presence of six major lineages (Lineages 1–6). The Euro-American 
(Lineage 4) and the two M. africanum lineages (Lineages 5 and 6) are the most common causes of human pulmo-
nary TB in West Africa9. The Cameroon genotype of Lineage 4 (also known as LAM-10) is dominant in much of 
West Africa10–14, although the Ghana genotype of Lineage 4, which often have spoligo patterns that belong to T1 
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clade, is also disseminated across almost all West African countries9. The two M. africanum lineages are generally 
restricted to West Africa and cases outside the region are often linked to West African migrants9. Although the 
prevalence of Beijing strains (lineage 2) is low in West Africa a high prevalence has been reported in Benin and 
Senegal, prompting concerns about its emergence in the region15,16.
Despite the availability of effective treatment, tuberculosis (TB) remains one of the leading causes of death 
from infectious disease globally. In 2015, the WHO estimated that there were over ten million new cases of TB 
globally and 1.5 million deaths17. In sub-Saharan Africa, the fight against TB faces unique challenges due to 
the combination of the HIV epidemic, the emergence of multidrug-resistant (MDR-TB) strains and inadequate 
infrastructure for TB case management18,19. A drug resistance survey of MTBC drug resistance in West Africa was 
conducted between 2008 and 2013 by the West African Nodes of Excellence for AIDS Tuberculosis and Malaria 
(WANETAM). The survey showed that the estimated prevalence of MDR-TB in West Africa was likely being 
underestimated and called for urgent measure to tackle the growing threat from MDR-TB in West Africa, one of 
the poorest regions in the world20.
Bamako, the capital city of Mali, is one of few West African cities that have a well-structured hierarchy for TB 
case management. However, in recent years, Bamako has been faced with an emerging threat from MDR-TB20,21. 
Between 2006 and 2014 a surveillance was carried out in Bamako, which included 522 patients treated for pul-
monary tuberculosis Bamako22. Phenotypic drug susceptibility testing on 337 unique isolates of MTBC showed 
resistance to at least one drug was found in 127 (37.7%) of which 75 (22.3%) were multidrug resistance (MDR)22. 
Spoligotyping confirmed that the most prevalent genotypes over the ten-year study period were MTB T1 (31.9%) 
and MTB LAM10 (Cameroon Genotype) (15.3%) from lineage 4 and M. africanum 2 (16.8%)23. These propor-
tions were similar to results published by Traore et al. in 2012 where he reported that the most prevalent gen-
otypes causing tuberculosis in Bamako were also MTB T1 (38.9%), M. africanum 2 (MAF2; 26.2%) and MTB 
LAM 10 (10.3%)21. Over the ten year surveillance period 50% of all cases of MDR-TB were associated with strains 
belonging to the T123 reinforcing the previous findings that the T1 genotype was associated with MDR-TB in 
Bamako21.
Genomics has recently become an important tool in clinical management of TB cases24–27. By studying the 
genomes of TB isolates, we can infer resistance to anti-TB drugs, unravel transmission chains and gain insights 
into the evolutionary mechanisms that shape the epidemiology of TB26,28–30. Here, we present insights into the evo-
lutionary mechanisms contributing to the rise of MDR-TB in Bamako. Although our sample size was limited, we 
tried to gain insights into the risk factors associated with MDR-TB in this setting using a logistic regression analy-
sis. Our data highlights how the evolution of drug resistance hampers the fight against TB in a low-resource setting.
Results
patient characteristics and genomic summary. A subset of randomly selected isolates from patients 
who had participated in study protocols at the University of Bamako were selected for whole genome sequencing 
(25). Isolates from 76 patients, who included 21 females and 55 males and individuals aged between 3 to 78 years, 
were analysed; these included 12 MDR-TB cases (Table 1). Most patients (n = 61, 80%) had not been previously 
treated for TB. While nine of the 15 retreatment cases (60%) had MDR-TB, only three among sixty-one new 
cases (5%) were MDR-TB. Sequencing reads mapped to the H37Rv reference genome with an average coverage 
of 33-fold (range 10 to 93-fold). De novo draft assemblies had an average of 4.4 million bases (range 4294898 to 
5984674) and an average N50 of 57958 (range 26213 to 82606).
phylogeny. A time dated maximum likelihood phylogeny was reconstructed from 8508 variant core genome 
sites using BEAST. All the human-associated lineages of MTBC from the “modern” clade (Lineages 2,3 & 4) were 
detected among patients from Mali (Table 2). The dominant lineage was the Euro-American lineage, Lineage 4, 
and within Lineage 4 the Cameroon genotype was the most prevalent genotype (n = 20, 26%) (Fig. 1).
The Ghana genotype was the second most common genotype isolated from patients in the genomics subset. 
The Ghana genotype was represented by 16 isolates—seven of these were MDR-TB, therefore, the Ghana genotype 
represents over half of the 12 MDR-TB isolates in the genomics dataset. Patients infected with the Ghana genotype 
MDR Non-MDR Total (%)
Total 12 64 76 (100)
HIV Status
Negative 11 51 62 (82%)
Positive 1 6 7 (9%)
Not Done 0 7 7 (9%)
Gender
Female 2 19 21 (28%)
Male 10 45 55 (72%)
Treatment History
New 3 58 61 (80%)
Retreatment 9 6 15 (20%)
Age (years)
0–15 1 2 3 (4%)
16–30 5 30 35 (46%)
Above 30 6 32 38 (50%)
Table 1. A table summarizing the patient characteristics of the study participants. The table shows the 
distribution of HIV status, gender, treatment history and age.
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were over 4 times more likely to have MDR-TB than patients infected with other genotypes but the association 
was not significant after adjusting for retreatment cases and whether the patients resided in Bamako or not (OR 
4.53, 95% CI 0.9–22.7, p value 0.067) (Table 3). Retreatment cases were 30 times more likely to have MDR-TB 
after adjusting for Ghana genotype and province of residence (OR 29.7, 95% CI 27.9–31.6, p value < 0.001).
Other Euro-American genotypes included the LAM genotype (n = 6), two H37Rv-like isolates and one isolate 
from the Uganda genotype. Four isolates of the Beijing genotype from Lineage 2, including one MDR-TB, formed 
a monophyletic clade where isolates differed by an average of 23 core genome SNVs. Our estimates suggest that 
our Beijing genotype isolates shared a common recent ancestor 40 years ago. Five patients were infected with 
MAF2 strains, but none were MDR, and another four were infected with the East Asian Indian lineage strains 
including one MDR-TB retreatment case.
Roles of the Ghana and cameroon genotypes of MtBc. Our phylogeny revealed a sub-clade of 
Ghana genotype isolates that diverged from a common recent ancestor approximately 30 years ago (95% HPD 
intervals 24.42–39.44) (Fig. 2). This sub-clade, which is highlighted in blue in Fig. 1, included seven MDR-TB 
and six non-MDR-TB isolates. On average, strains within this cluster differed by 12 core-genome SNVs. The most 
divergent pair of strains within this cluster differed by 24 core genome SNVs. The katG Ser315Thr isoniazid resist-
ance mutation was conserved in all the isolates and in one non-MDR isoniazid resistant isolate. Three isoniazid 
resistant isolates also acquired the fabG1 inhA promoter-region mutation that is known to confer isoniazid and 
ethionamide resistance. MDR-TB isolates acquired rifampicin resistance through several different mutations in 
the rpoB gene (Fig. 2).
Phylogenetic dating suggested that the Cameroon genotype isolates diverged from a common recent ances-
tor approximately 161 years ago (95% HPD intervals 129.52–195.39) to form three clusters (Fig. 3). The cluster 
of closely related genomes highlighted in pink in Fig. 1 was a sub-clade of the Cameroon genotype clade that 
encompassed eight non-MDR isolates. This sub clade was highly conserved and isolates within it differed by 
average pairwise distance of 8 core genome SNVs (range 0 to 13 SNVs). We estimated that this cluster emerged 
approximately 22 years ago (95% HPD intervals 15.32–29.61) with within-cluster internal node ages ranging from 
1.75 years to 16.55 years (Fig. 3).
evidence of community transmission. Potential transmission clusters were identified as sub clades 
within the phylogeny that had an average pairwise genetic distance of 12 or less SNVs. Two clusters were identi-
fied, a Cameroon genotype cluster and a Ghana genotype cluster, which were illustrated by highlighting the sub-
clades on the phylogenetic tree in Figs. 1–3. The average pairwise genetic differences in the Cameroon genotype (7 
SNVs) cluster was significantly lower than the average distance in the Ghana genotype cluster (p value < 0.0001) 
(Fig. 4). The median pairwise distance between patients’ residential provinces as approximately 11 km in both 
clusters (Fig. 4) as most patients resided in provinces within Bamako.
Further evidence of community transmission was the identification of the same strain (0 SNV difference) 
from different patients on four occasions (marked in Fig. 1). In case 1 the strain was a Cameroon genotype 
strain, which was not from the highlighted transmission cluster. The strain was isolates from two patients in 
Bamako in 2013 residing in provinces 8 km apart. Case 2 also involved a Cameroon genotype strain, which was 
part of the transmission cluster. This strain was isolated from a patient in Senou 2012 and a second patient in 
Daoudabougou, Bamako in 2013 (~20 km apart). Moreover, this strain was closely related (2 SNV difference) 
to another strain isolated from a resident Kayes (~500 km from Bamako) in 2013. Case 3 involved a strain from 
the X-type genotype, which was found in two patients in residing in Bamako, Yirimadio and Kalaban-Coura (~ 
10 km apart), in 2010. In case 4 the strain was within the Ghana genotype transmission cluster. Both patients, a 
male and a female aged 18 and 4 years respectively, were resident in Bamako in provinces 7.5 km apart and were 
both recruited in June 2013. This strain was closely related (3 SNV difference) to two other strains within the 
transmission cluster, one isolated from resident of Bamako in 2013 and the second one isolated in 2007 from a 
patient whose provincial domicile was not known.
Lineage Clade MDR Non-MDR Total (%)
2 Beijing 1 3 4 (5.3)
3 EAI 1 3 4 (5.3)
4
Cameroon 2 18 20 (26.3)
Ghana 7 9 16 (21.1)
H37Rv 1 1 2 (2.6)
Haarlem 0 10 10 (13.2)
LAM 0 6 6 (7.9)
Uganda 0 1 1 (1.3)
X-type 0 8 8 (10.5)
6 MAF2 0 5 5 (6.6)
Total 12 64 76
Table 2. A table showing the genotypic distribution of the isolates recovered from patients. The table shows 
the distribution of the major lineages of MTBC and the distribution of genotypes inferred from whole genome 
sequencing.
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Discussion
Estimating the burden of drug resistant tuberculosis in Mali has been challenging due to political instability and 
weak infrastructure. Laboratory based drug resistance surveillance carried out in Bamako between 2006 and 2014 
showed that the levels of MDR-TB among patients has remained constant and relatively high22. Our study employs 
whole genome sequencing to study the evolutionary mechanisms driving the rise of MDR-TB in Mali in recent 
times and the emergence of virulent lineages of MTBC using a subset of isolates reported in Gehre et al. (25).
Our data shows that an important driver of MDR-TB in Bamako is a sub-clade of the Ghana genotype, which often 
has spoligo typing patters belonging to the T1 family. This family has previously been implicated with a higher likeli-
hood of resistance compared to other genotypes21. The MDR-TB Ghana genotype sub-clade emerged approximately 
Figure 1. A time-dated phylogenetic tree of 76 MTBC isolates from pulmonary tuberculosis patients treated 
in Bamako, Mali between 2006 and 2013. Phylogenetic tree is shown alongside metadata including genotype, 
residential province, MDR-TB status based on phenotypic testing, HIV status and treatment history (new case 
or retreatment). The numbers on the x-axis show the number of years from the root. Closely related isolates 
from the Ghana genotype and Cameroon genotype are highlighted in blue and pink boxes respectively. White 
boxes in the metadata indicate missing data. The dashed line is the H37Rv reference genome. Branches are 
coloured based on genotype and labelled with SNP barcoding genotypes. Heat maps show phenotypic resistance 
and presence of resistance genotypes for first line drugs.
Co-variates Levels
MDR-TB 
count (%)
Odds ratio 
(95% CI) p-value
Genotype
Others 5 (8.3) —
Ghana 7 (43.8) 4.5 (0.9–22.7) 0.07
Treatment status
New case 3 (4.9) —
Retreatment 9 (60) 108.7 (27.9–31.6) <0.001
Table 3. A summary of the MDR-TB risk factor analysis. The table shows the odds ratio, p-value and 95% 
confidence intervals for MDR-TB likelihood for patients infected with the Ghana genotype compared to other 
genotypes and retreatment cases compared to new cases.
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Figure 2. A time-dated phylogenetic tree of all Ghana genotype isolates in this dataset to highlight the 
evolution of MDR-TB in this lineage. Phylogeny shown alongside MDR status, treatment status, HIV 
status, phenotypic resistance profiles and resistance mutations for first line drugs are listed. Heat maps show 
phenotypic resistance and presence of resistance genotypes for first line drugs. Internal nodes are labelled with 
age in years.
Figure 3. A time-dated phylogenetic tree of all Cameroon genotype isolates in our dataset. The phylogeny is 
shown alongside patient metadata and date of isolation to highlight the evolution of this emerging genotype in 
Bamako. Internal nodes are labelled with age in years.
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30 years ago, most likely through the initial acquisition on the katG Ser415Thr isoniazid resistant mutation. Isoniazid 
resistance probably presented a selective advantage to the ancestral clone, allowing it to form divergent sub-clones that 
acquired rifampicin resistance through different mechanisms and is now the leading cause of MDR-TB in Bamako.
The main genotypes of MTBC known to cause tuberculosis in Bamako are the T1 family, Cameroon genotype 
(LAM10) and the M. Africanum West Africa 2 lineage strains21,23. Our data suggests that the Cameroon geno-
type is on the rise in Bamako compared to recent estimates21 and there is evidence of community transmission. 
Although the emerging Cameroon genotype strains are non MDR-TB, the situation should be carefully moni-
tored. In Nigeria, a neighbouring West African country, we have seen evidence of widespread MDR-TB within 
the Cameroon genotype and signs of community transmission31.
The first report of Beijing strains causing tuberculosis in Bamako was in 2008 when unrelated strains were detected 
in two patients with active pulmonary tuberculosis32. Here we identified a clade of related Beijing isolates that differed 
on average by 22 SNVs (range 12 to 30) including one MDR-TB isolate. The Beijing genotype has emerged around the 
world33,34 and has demonstrated the ability to spread rapidly once introduced into a new population35. Bioinformatics 
approaches have identified mutations in virulence genes that are unique to the Beijing genotype36 and mutations in 
immune response associated genes that may aid host-pathogen co-evolution to the detriment of TB control37. The 
Beijing genotype has also been linked to MDR-TB in other settings38. Tuberculosis surveillance in Mali would be 
helpful in identifying the extent to which the Beijing and other virulent genotypes have spread in the community.
A disproportionate number of MDR-TB cases end up in retreatment or treatment failure. This is because in 
Bamako only retreatment or treatment failure patients were subjected to drug susceptibility testing at the National 
Tuberculosis Reference Laboratory. New cases with MDR-TB would not be detected unless they were enrolled in 
research protocols, at the SEREFO program where all isolates undergo routine phenotypic or genotypic suscep-
tibility testing22. Implementing drug susceptibility testing across all public hospitals is not cost-effective but the 
Hain MTBDRplus Line Probe Assay could provide an effective screening tool to detect the most common forms 
of isoniazid and rifampicin resistance.
conclusion
MDR-TB is a growing public health concern in Bamako. MDR-TB in Bamako is often caused by a 30-year old sub 
clade of the Ghana genotype. Introducing molecular susceptibility testing as a screening tool in public hospitals 
will improve the early detection of MDR-TB, improve treatment outcomes and curb the spread of the MDR-TB 
including the Ghana genotype MDR-TB sub clade.
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Methods
Demographics of study area. The study participants from Mali were recruited in the capital city Bamako, 
where according to the Ministry of Health more than a third of all TB cases in Mali were managed in 201439. 
Bamako is divided into six districts and each district has a TB referral health centre that is equipped with diag-
nosis and treatment facilities. Our isolates were collected at the University Teaching Hospital as part of research 
protocols, which acts as the principal TB referral centre. Retreatment cases from across Mali are referred to the 
University Teaching Hospital for further investigation and treatment.
ethical approval and informed consent. All study protocols were approved by the ethic committee of 
the faculty of medicine, pharmacy and dentistry of Bamako as well as the MRC Unit The Gambia at LSHTM and 
Gambia Government joint ethics committee. Signed informed consent was obtained from all patients and from 
the legal guardian for patients under 18 years of age. All methods were carried out in accordance with relevant 
guidelines and regulations.
Study isolates. In a surveillance of tuberculosis between 2006 and 2014, which included 522 patients treated 
in Bamako, co-author Diarra and colleagues22. From this dataset a subset of 208 isolates were sent to MRC Unit 
The Gambia at LSHTM, as part of the WANETAM survey on drug resistant tuberculosis in West Africa20. This is 
an ad hoc dataset whereby 85 isolates were chosen at random without any set criteria.
Sub cultured mycobacterial isolates were sent to the MRC Unit The Gambia at LSHTM for viability and anti-
microbial susceptibility testing. Isolates were sub-cultured onto MGIT 960 system (Becton Dickinson, Oxford 
Science Park, Oxford, UK) for viability testing. Positive cultures were tested for purity by inoculation on blood 
agar and followed up only if there was no growth after 24 hours incubation. The presence of MTBC was con-
firmed by Ziehl–Neelsen staining. Susceptibility testing for the first-line drugs was performed on the MGIT 960 
system (Becton Dickinson, Oxford Science Park, Oxford, UK) according to manufacturer’s instructions40: strep-
tomycin (STR, 1 µg/mL), isoniazid (INH, 0.1 µg/mL), rifampicin (RIF, 1 µg/mL), and ethambutol (EMB, 4.5 µg/
mL). Multidrug-resistant strains (resistant to isoniazid and rifampicin) were further tested for susceptibility to 
the second-line drugs capreomycin (CAP, 2.5 µg/mL), ofloxacin (OFX, 2 µg/mL), and ethionamide (ETH, 5 µg/
mL) (Sigma-Aldrich, St. Louis, Mo, USA)20. The MRC Unit The Gambia at LSHTM TB Diagnostics Laboratory 
participates in external quality assurance from the National External Quality Assessment Service (NEQAS), UK 
(http://www.ukneqas.org.uk/) and is ISO15189:2012 accredited for’ first- and second-line DST together with 
other TB diagnostic assays.
Whole genome sequencing. In order to extract whole-genomic DNA isolates were grown in Middlebrooks 
7H9 liquid medium (Sigma Aldrich, Gillingham, Dorset, UK) for 3–8 weeks and the presence of MTBC was 
confirmed by the rapid test CapiliaTM TB-Neo (Sigma Aldrich, Gillingham, Dorset, UK) or BD MGIT™ TBc 
(Becton, Dickinson and Company, Oxford Science Park, Oxford, UK). To test for purity the culture medium 
was streaked onto blood agar and incubated at 37 °C for 48 hours. Finally genomic DNA extraction was per-
formed using the cetyl trimethylammonium bromide (CTAB) method41. Genomic DNA libraries were prepared 
for whole genome sequencing using the Nextera XT library prep kit according to manufacturer’s instructions 
(Illumina, Little Chesterford, UK) and sequenced on an Illumina MiSeq following the manufacturer’s instructions 
(Illumina, Little Chesterford, UK).
Genomic and phylogenetic analysis. An adhoc subset of eighty-five isolates of MTBC were selected from 
208 archived Malian isolates for whole-genome sequencing. Seven isolates that had low coverage (<10X) and 
two isolates that had no patient metadata or antimicrobial susceptibility profiles were excluded from the analysis. 
Sequencing reads were uploaded on the PhyResSe webtool for lineage assignment and antimicrobial susceptibility 
prediction29. Phylogenetic lineages were inferred based on the whole genome single nucleotide polymorphism 
typing scheme described by Homolka and colleagues42.
For each isolate de novo contigs were generated from the paired-end sequencing reads using SPAdes (kmers: 
21, 33, 55, 77, 99 and 127)43. To correct assemblies, SOAPaligner v2.21 was used to to remap sequencing reads 
onto each assembly and bases in the assembly were filtered based on a quality score <20 and <10 reads mapped. 
Each assembly was mapped to the H37Rv reference genome using the nucmer function in MUMmer44 to gener-
ate a consensus sequence and all concensus sequences were compiled in a multiple sequence alignment with the 
reference genome. Using custom Perl scripts all repeat regions identified by Sergeant et al.45 were removed from 
the alignment and the core genome was inferred from the multiple sequence alignment as sites conserved in all 
isolates46,47.
Single nucleotide variants (SNVs) were extracted from the core genome multiple sequence alignment using 
custom Perl scripts and were uploaded on the Bayesian Evolutionary Analysis Sampling Trees (BEAST Geo Shere 
package version 1.1.2) tool48. A time dated maximum likelihood phylogeny was reconstructed from variable 
sites in the core genome using a relaxed clock gamma time reversible model with substitution rates estimated 
from the sequence alignment data and a Yule model for birth rate. Date of sample collection (year and month of 
collection) and GPS coordinates for patients’ residential province were uploaded as traits. The phylogenetic tree 
was visualised in the Interactive Tree of Life (iTol)49 and FigTree (Version 1.4.2) and annotated using Inkscape50. 
A multifasta containing variant core genome sites was uploaded on MEGA 7 and a distant matrix was generated 
based on the pairwise number of differences between isolates.
MDR-tB risk factor analysis. The associated metadata for each patient was uploaded onto Stata version 
12.0 for statistical analysis. A logistic regression analysis using the Chi square test was performed to test whether 
isolates belonging to the Ghana genotype were more likely to be MDR-TB than isolates belonging to other 
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lineages. We controlled for whether the patients were retreatment cases of new cases and error bars were adjusted 
for based on the province of origin of the patient.
Study limitations. The limitation of the study is that patients were recruited from the University teaching 
hospital, which is a referral center. The prevalence of genotypes in our dataset may not be an exact representation 
of the prevalence of genotypes in the communities within Bamako.
Data declaration. The sequencing reads generated for the analysis presented in this paper have been 
uploaded onto the European Nucleotide Archives under the project accession number PRJEB27446.
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